Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesSaxagliptin: DPP-4 inhibitor approved for the treatment of type 2 diabetes mellitus
Formulary , 09/17/09
Saxagliptin is an inhibitor of the dipeptidyl peptidase–4 enzyme. By inhibiting DPP–4, saxagliptin slows the inactivation of the incretin hormones, which increases their concentrations in the bloodstream and reduces both fasting and postprandial glucose concentrations in a glucose–dependent manner. Saxagliptin was approved on July, 2009, for use as monotherapy or as part of combination therapy as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Related Articles
Prevention of Type 2 Diabetes: Risk Status, Clinic, and Community
Journal of General Internal Medicine, 11/09/09
Relevance Score: 96%
Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset
Diabetologia - Clinical and Experimental Diabetes and Metabolism, 10/19/09
Relevance Score: 95%
Cigarette smoking is an independent risk factor for type 2 diabetes: a four-year community-based prospective study
Clinical Endocrinology, 10/16/09
Relevance Score: 94%
Periodontal Disease – The Overlooked Diabetes Complication
Nephrology Nursing Journal, 10/07/09
Relevance Score: 94%
Testing for monogenic diabetes among children and adolescents with antibody-negative clinically defined Type 1 diabetes
Diabetic Medicine, 10/05/09
Relevance Score: 94%
Today in Drug Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
FDA Drug Approval Summary: Bevacizumab (Avastin) as Treatment of Recurrent Glioblastoma Multiforme
The Oncologist, 12/03/09
Ustekinumab (Stelara): First-in-class human monoclonal antibody approved for treatment of moderate-to-severe plaque psoriasis
Formulary , 12/02/09
Safety concerns slow new drug review and approval processes
Formulary , 12/02/09
Today in Other Drugs...keeping you current
Receive free subspecialty "5-minute updates" via email
Clinical applications for topical 5-fluorouracil in the treatment of dermatological disorders
Journal of Dermatological Treatment , 12/04/09
Non-psoriatic dermatologic uses of monoclonal antibody therapy
Journal of Dermatological Treatment , 12/04/09
Does Simvastatin Cause More Myotoxicity Compared with Other Statins
Annals of Pharmacotherapy, 12/03/09
Sponsor
Article Search
Sponsor